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Abstrat
The G-protein oupled reeptor (GPCR) superfamily is urrently the largest lass of ther-
apeuti targets. In silio predition of interations between GPCRs and small moleules is
therefore a ruial step in the drug disovery proess, whih remains a daunting task due to the
diulty to haraterize the 3D struture of most GPCRs, and to the limited amount of known
ligands for some members of the superfamily. Chemogenomis, whih attempts to harater-
ize interations between all members of a target lass and all small moleules simultaneously,
has reently been proposed as an interesting alternative to traditional doking or ligand-based
virtual sreening strategies.
We propose new methods for in silio hemogenomis and validate them on the virtual
sreening of GPCRs. The methods represent an extension of a reently proposed mahine learn-
ing strategy, based on support vetor mahines (SVM), whih provides a exible framework to
inorporate various information soures on the biologial spae of targets and on the hemial
spae of small moleules. We investigate the use of 2D and 3D desriptors for small moleules,
and test a variety of desriptors for GPCRs. We show fo instane that inorporating informa-
tion about the known hierarhial lassiation of the target family and about key residues in
their inferred binding pokets signiantly improves the predition auray of our model. In
partiular we are able to predit ligands of orphan GPCRs with an estimated auray of 78.1%.
1 Introdution
The G-protein oupled reeptor (GPCR) superfamily is omprised of an estimated 600-1,000 mem-
bers and is the largest known lass of moleular targets with proven therapeuti value. They are
ubiquitous in our body, being involved in regulation of every major mammalian physiologial sys-
tem (Bokaert and Pin, 1999), and play a role in a wide range of disorders inluding allergies,
ardiovasular dysfuntion, depression, obesity, aner, pain, diabetes, and a variety of entral ner-
vous system disorders (Deshpande and Penn, 2006; Hill, 2006; Catapano and Manji, 2007). They
∗
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are integral membrane proteins sharing a ommon global topology that onsists of seven trans-
membrane alpha helies, an intraellular C-terminal, an extraellular N-terminal, three intraellular
loops and three extraellular loops. There are four main lasses of GPCRs (A, B, C and D) depend-
ing on their sequene similarity (Horn et al., 2003). Their loation on the ell surfae makes them
readily aessible to drugs, and 30 GPCRs are the targets for the majority of best-selling drugs,
representing about 40% of all presription pharmaeutials on the market (Fredholm et al., 2007).
Besides, the human genome ontains several hundred unique GPCRs whih have yet to be assigned
a lear ellular funtion, suggesting that they are likely to remain an important target lass for new
drugs in the future (Lin and Civelli, 2004).
Prediting interations in silio between small moleules and GPCRs is not only of partiular
interest for the drug industry, but also a useful step for the eluidation of many biologial proess.
First, it may help to deipher the funtion of so-alled orphan GPCRs, for whih no natural ligand
is known. Seond, one a partiular GPCR is seleted as a target, it may help in the seletion of
promising moleule andidates to be sreened in vitro against the target for lead identiation.
In silio virtual sreening of GPCRs with lassial approahes is however a daunting task for
at least two reasons. First, the 3D strutures are urrently known for only two GPCRs (bovine
rhodopsin and human β2-adrenergi reeptor). Indeed, GPCRs, like other membrane proteins, are
notoriously diult to rystallize. As a result, doking strategies for sreening small moleules
against GPCRs are often limited by the diulty to model orretly the 3D struture of the tar-
get. To irumvent the lak of experimental strutures, various studies have used 3D strutural
models of GPCRs built by homology modeling using bovine rhodopsin as a template struture.
Doking a library of moleules into these modeled strutures allowed the reovery of known lig-
ands (Evers and Klabunde, 2005), and even identiation of new ligands (Cavasotto et al., 2003).
However, doking methods still suer from doking and soring inauraies, and homology models
are not always reliable-enough to be employed in target-based virtual sreening. Methods have
been proposed to enhane the quality of the models by global optimization and exible dok-
ing (Cavasotto et al., 2003), or by using dierent sets of reeptor models. Nevertheless, these
methods are expeted to show limited performanes for GPCRs sharing low sequene similarity
with rhodopsin, espeially in the ase of reeptors belonging to lasses B, C and D. Alternatively,
ligand-based strategies, also known as quantitative struture-ativity relationship (QSAR), attempt
to predit new ligands from previously known ligands, often using statistial or mahine learning
approahes. Ligand-based approahes are interesting beause they do not require the knowledge of
the target 3D struture and an benet from the disovery of new ligands. However, their auray
is fundamentally limited by the amount of known ligands, and degrades when few ligands are known.
Although these methods were suessfully used to retrieve strong GPCR binders (Rolland et al.,
2005), they are eient for lead optimization within a previously identied moleular saold, but
are not appropriate to identify new families of ligands for a target. At the extreme, they annot be
pursued for the sreening of orphan GPCRs.
Instead of fousing on eah individual target independently from other proteins, a reent trend in
the pharmaeutial industry, often referred to as hemogenomis, is to sreen moleules against sev-
eral targets of the same family simultaneously (Kubinyi et al., 2004; Jaroh and Weinmann, 2006).
This systemati sreening of interations between the hemial spae of small moleules and the
biologial spae of protein targets an be thought of as an attempt to ll a large 2D interation
matrix, where rows orrespond to targets, olumns to small moleules, and the (i, j)-th entry of the
matrix indiates whether the j-th moleule an bind the i-th target. While in general the matrix
may ontain some desription of the strength of the interation, suh as the assoiation onstant of
the omplex, we will fous in this paper on a simplied desription that only dierentiates binding
from non-binding moleules, whih results in a binary matrix of target-moleule pairs. This matrix
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is already sparsely lled with our urrent knowledge of protein-ligand interations, and hemoge-
nomis attempts to ll the holes. While lassial doking or ligand-based virtual sreening strategies
fous on eah single row independently from the others in this matrix, i.e., treat eah target in-
dependently from eah others, the hemogenomis approah is motivated by the observation that
similar moleules an bind similar proteins, and that information about a known interation be-
tween a ligand and a GPCR ould therefore be a useful hint to predit interation between similar
moleules and similar GPCRs. This an be of partiular interest when, for example, a partiular
target has few or no known ligands, but similar proteins have many: in that ase it is tempting to
use the information about the known ligands of similar proteins for a ligand-based virtual sreening
of the target of interest. In this ontext, we an formally dene in silio hemogenomis as the
problem of prediting interations between a moleule and a ligand (i.e., a hole in the matrix) from
the knowledge of all other known interations or non-interations (i.e., the known entries of the
matrix).
Reent reviews (Kubinyi et al., 2004; Jaroh and Weinmann, 2006; Klabunde, 2007; Rognan,
2007) desribe several strategies for in silio hemogenomis. A rst lass of approahes, alled
ligand-based hemogenomis by Rognan (2007), pool together targets at the level of families (suh
as GPCR) or subfamilies (suh as purinergi GPCR) and learn a model for ligands at the level of the
family (Balakin et al., 2002; Klabunde, 2006). Other approahes, termed target-based hemogenomi
approahes by Rognan (2007), luster reeptors based on ligand binding site similarity and again
pool together known ligands for eah luster to infer shared ligands (Frimurer et al., 2005). Finally,
a third strategy termed target-ligand approah by Rognan (2007) attempts to predit ligands for a
given target by leveraging binding information for other targets in a single step, that is, without
rst attempting to dene a partiular set of similar reeptors. This strategy was pioneered by
Bok and Gough (2005) to predit ligands of orphan GPCR. They merged desriptors of ligands and
targets to desribe putative ligand-reeptor omplexes, and used SVM to disriminate real omplexes
from ligand-reeptors pairs that do not form omplexes. Erhan et al. (2006) followed a similar idea
with dierent desriptors, and showed in partiular that the SVM formulation allows to generalize
the use of vetors of desriptors to the use of positive denite kernels to desribe the hemial and
the biologial spae in a omputationally eient framework. Erhan et al. (2006) were not able to
show, however, signiant benets with respet to the individual approah that learns a separate
lassier for eah GPCR (exept in the ase of orphan GPCRs, for whih their approah performed
better than the baseline random lassier). Reently, in the ontext of prediting interations
between peptides and dierent alleles of MHC-I moleules, Jaob and Vert (2008) followed a similar
approah and highlighted the importane of hoosing adequate desriptors for small moleules and
targets. They obtained state-of-the-art predition auray for most MHC-I allele, in partiular for
those with few known binding peptides.
In this paper we go one step further in this diretion and present an in silio hemogenomis
approah speially tailored for the sreening of GPCRs, although the method ould in priniple
be adapted to other lasses of therapeuti targets. We follow the idea of Bok and Gough (2005)
and the algorithmi trik of Erhan et al. (2006), whih allows us to systematially test a variety of
desriptors for both the moleules and the GPCRs. We test two families of 2D and 3D desriptors
to desribe moleules, inluding a new 3D kernel, and six ways to desribe GPCRs, inluding a
desription of their relative positions in urrent hierarhial lassiations of the superfamily, and
information about key residues likely to be in ontat with the ligand. We test the approah on
the data of the GLIDA database (Okuno et al., 2006), whih ontains 34686 reported interations
between human GPCRs and small moleules, and observe that the hoie of the desriptors has a
signiant impat on the auray of the models. In partiular, the best results are reahed when
using the desription of GPCRs within the hierarhial lassiation of the superfamily, ombined
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with a set of 2D desriptors of small moleules. This allows us to obtain dramati improvements of
the predition auray with respet to the individual learning setting. In an experiment where we
simulate the predition of ligands for orphan GPCRs, we obtain auraies of 78.1%, signiantly
above the 50% baseline auray of a random preditor.
2 Method
In this setion, we rst review the methods proposed by Bok and Gough (2005); Erhan et al. (2006)
for in silio hemogenomis with SVM, before presenting the partiular desriptors we propose to
use for moleules and GPCRs within this framework.
2.1 In silio hemogenomis with mahine learning
We onsider the problem of prediting interations between GPCRs and small moleules. For this
purpose we assume that a list of target/small moleule pairs {(t1,m1), . . . , (tn,mn)}, known to
interat or not, is given. Suh information is often available as a result of systemati sreening
ampaigns in the pharmaeutial industry, or on dediated databases. Our goal is then to reate a
model to predit, for any new andidate pair (t,m), whether the small moleule m is likely to bind
the GPCR t.
A general method to reate the preditive model is to follow these four steps:
1. Choose ntar desriptors to represent eah GPCR target t in the biologial spae by a ntar-
dimensional vetor Φtar(t) = (Φ
1
tar(t), . . . ,Φ
ntar
tar (t));
2. In parallel, hoose nmol desriptors to represent eah moleule m in the hemial spae by a
nmol-dimensional vetor Φmol(m) = (Φ
1
mol(m), . . . ,Φ
nmol
mol (m));
3. Derive a vetor representation of a andidate target/moleule omplex Φpair(t,m) from the
representations of the target Φtar(t) and of the moleule Φmol(m);
4. Use a statistial or mahine learning method to train a lassier able to disriminate be-
tween binding and non-binding pairs, using the training set of binding and non-binding pairs
{Φpair(t1,m1), . . . ,Φpair(tn,mn)}
While the rst two steps (seletion of desriptors) may be spei to eah partiular hemogenomis
problem, the last two steps dene the partiular strategy used for in silio hemogenomis. For
example, Bok and Gough (2001, 2005) proposed to onatenate the vetors Φtar(t) and Φmol(m)
to obtain a (ntar+nmol)-dimensional vetor representation of the ligand-target omplex Φpair(t,m),
and to use a SVM as a mahine learning engine. Erhan et al. (2006) followed a slightly dierent
strategy for the third step, by forming desriptors for the pair (t,m) as produt of small moleule
and target desriptors. More preisely, given a moleule m desribed by a vetor Φmol(m) and a
GPCR t desribed by a vetor Φtar(t), the pair (t,m) is represented by the tensor produt:
Φpair(t,m) = Φtar(t)⊗ Φmol(m) , (1)
that is, a (ntar×nmol)-dimensional vetor whose entries are produts of the form Φ
i
tar(t)×Φ
j
mol
(m),
for 1 ≤ i ≤ ntar and 1 ≤ j ≤ nmol. A SVM is then used as an inferene engine, to estimate a
linear funtion f(t,m) in the vetor spae of target/moleule pairs, that takes positive values for
interating pairs and negative values for non-interating ones.
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The main motivation for using the tensor produt (1) is that it provides a systemati way to
enode orrelations between small moleule and target features. For example, in the ase of binary
desriptors, the produt of two features is 1 if both the moleule and the target desriptors are 1,
and zero otherwise, whih amounts to enode the simultaneous presene of partiular features of the
moleule and of the target that may be important for the formation of a omplex. A potential issue
with this approah, however, is that the size of the vetor representation ntar ×nmol for a pair may
be prohibitively large for pratial omputation and manipulation. For example, using a vetor of
moleular desriptors of size 1024 for moleules, and representing a protein by the vetor of ounts of
all 2-mers of amino-aids in its sequene (dt = 20× 20 = 400) results in more than 400k dimensions
for the representation of a pair. As pointed out by Erhan et al. (2006), this omputational obstale
an however be overome when a SVM is used to train the linear lassier, thanks to a trik often
referred to as the kernel trik. Indeed, a SVM does not neessarily need the expliit omputation of
the vetors representing the omplexes in the training set to train a model. What it needs, instead,
is the inner produts between these vetors, and a lassial property of tensor produts is that the
inner produt between two tensor produts Φpair(t,m) and Φpair(t
′,m′) is the produt of the inner
produt between Φtar(t) and Φtar(t
′), on the one hand, and the inner produt between Φmol(m)
and Φmol(m
′), on the other hand. More formally, this property an be written as follows:
(Φtar(t)⊗ Φmol(m))
⊤
(
Φtar(t
′)⊗ Φmol(m
′)
)
= Φtar(t)
⊤Φtar(t
′)× Φmol(m)
⊤Φmol(m
′) , (2)
where u⊤v = u1v1+ . . .+udvd denotes the inner produt between two d-dimensional vetors u and
v. In other words, the SVM does not need to ompute the ntar×nmol vetors to desribe eah pair,
it only omputes the respetive inner produts in the target and ligand spaes, before taking the
produt of both numbers.
This exibility to manipulate moleule and target desriptors separately an moreover be om-
bined with other triks that sometimes allow to ompute eiently the inner produts in the target
and ligand spaes, respetively. Many suh inner produts, also alled kernels, have been developed
reently both in omputational biology (Shölkopf et al., 2004) and hemistry (Kashima et al., 2003;
Gärtner et al., 2003; Mahé et al., 2005), and an be easily ombined within the hemogenomis
framework as follows: if two kernels for moleules and targets are given as:
Kmol(m,m
′) = Φmol(m)
⊤Φmol(m
′),
Ktar(t, t
′) = Φtar(t)
⊤Φtar(t
′),
(3)
then we obtain the inner produt between tensor produts, i.e., the kernel between pairs, by:
K
(
(t,m), (t′,m′)
)
= Ktar(t, t
′)×Kmol(m,m
′). (4)
In summary, as soon as two vetors of desriptors or kernels Klig and Ktar are hosen, we an
solve the in silio hemogenomis problem with an SVM using the produt kernel (4) between pairs.
The partiular desriptors or kernels used should ideally enode properties related to the ability of
similar moleules to bind similar targets or ligands respetively.
In the next two subsetions, we present dierent possible hoies of desriptors  or kernels 
for small moleules and GPCRs, respetively.
2.2 Desriptors for small moleules
The problem of expliitly representing and storing small moleules as nite-dimensional vetors
has a long history in hemoinformatis, and a multitude of moleular desriptors have been pro-
posed (Todeshini and Consonni, 2002). These desriptors inlude in partiular physiohemial
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properties of the moleules, suh as its solubility or logP, desriptors derived from the 2D struture
of the moleule, suh as fragment ounts or strutural ngerprints, or desriptors extrated from
the 3D struture (Gasteiger and Engel, 2003). Eah lassial ngerprint vetor and vetor repre-
sentation of moleules dene an expliit hemial spae in whih eah moleule is represented
by a nite-dimensional vetor, and these vetor representations an obviously be used as suh to
dene kernels between moleules (Azenott et al., 2007). Alternatively, some authors have reently
proposed some kernels that generalize some of these sets of desriptors and orrespond to inner prod-
uts between large- or even innite-dimensional vetors of desriptors. These desriptors enode,
for example, the ounts of an innite number of walks on the graph desribing the 2D struture
of the moleules (Kashima et al., 2004; Gärtner et al., 2003; Mahé et al., 2005), or various features
extrated from the 3D strutures (Mahé et al., 2006; Azenott et al., 2007).
In this study we selet two existing kernels, enoding respetively 2D and 3D strutural infor-
mation of the small moleules, and propose a new 3D kernel:
• The 2D Tanimoto kernel. Our rst set of desriptors is meant to haraterize the 2D struture
of the moleules. For a small moleule m, we dene the vetor Φmol(m) as the binary vetor
whose bits indiate the presene or absene of all linear graph of length u or less as subgraphs
of the 2D struture of l. We hose u = 8 in our experiment, i.e., haraterize the moleules
by the ourrenes of linear subgraphs of length 8 or less, a value previously observed to
give good results in several virtual sreening tasks (Mahé et al., 2005). Moreover, instead of
diretly taking the inner produt between vetors as in (3), we use the Tanimoto kernel:
Kligand(l, l
′) =
Φlig(l)
⊤Φlig(c
′)
Φlig(l)⊤Φlig(l) + Φlig(l′)⊤Φlig(l′)− Φlig(l)⊤Φlig(l′)
, (5)
whih was proven to be a valid inner produt by Ralaivola et al. (2005), giving very ompetitive
results on a variety of QSAR or toxiity predition experiments.
• 3D pharmaophore kernel While 2D strutures are known to be very ompetitive in ligand-
based virtual sreening (Azenott et al., 2007), we reasoned that some spei 3D onforma-
tions of a few atoms or funtional groups may be responsible for the interation with the target.
Thus, we deided to test desriptors representing the presene of potential 3-point pharma-
ophores. For this, we used the 3D pharmaophore kernel proposed by Mahé et al. (2006),
that generalizes 3D pharmaophore ngerprint desriptors. This approah implies the hoie
of a 3D onformer for eah moleule. In absene of suient data available for bound ligands
in GPCR strutures, we hose to build a 3D version of the ligand base in whih moleules
are represented in an estimated minimum energy onformation. For eah of the 2446 retained
ligands, 25 onformers were generated with the Omega program (OpenEye Sienti Software)
using standard parameters, exept for a 1 RMSD lustering of the onformers, instead of the
0.8 default value. A 3D ligand base was generated by keeping the onformer of lowest energy
for eah ligand. Partial harges were alulated for all atoms using the molharge program
(OpenEye Sienti Software) with standard parameters. This ligand base was then used to
alulate a 3D pharmaophore kernel for moleules (Mahé et al., 2006).
We used the freely and publily available ChemCPP
1
software to ompute the 2D and 3D
pharmaophore kernel.
1
Available at http://hempp.soureforge.net.
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2.3 Desriptors for GPCRs
SVM and kernel methods are also widely used in bioinformatis (Shölkopf et al., 2004), and a
variety of approahes have been proposed to design kernels between proteins, ranging from kernels
based on the amino-aid sequene of a protein (Jaakkola et al., 2000; Leslie et al., 2002; Tsuda et al.,
2002; Leslie et al., 2004; Vert et al., 2004; Kuang et al., 2005; Cuturi and Vert, 2005) to kernels
based on the 3D strutures of proteins (Dobson and Doig, 2005; Borgwardt et al., 2005; Qiu et al.,
2007) or on the pattern of ourrenes of proteins in multiple sequened genomes (Vert, 2002). These
kernels have been used in onjuntion with SVM or other kernel methods for various tasks related
to strutural or funtional lassiation of proteins. While any of these kernels an theoretially
be used as a GPCR kernel in (4), we investigate in this paper a restrited list of spei kernels
desribed below, aimed at illustrating the exibility of our framework and test various hypothesis.
• The Dira kernel between two targets t, t′ is:
KDirac(t, t
′) =
{
1 if t = t′ ,
0 otherwise.
(6)
This basi kernel simply represents dierent targets as orthonormal vetors. From (4) we
see that orthogonality between two proteins t and t′ implies orthogonality between all pairs
(l, t) and (l′, t′) for any two small moleules c and c′. This means that a linear lassier for
pairs (l, t) with this kernel deomposes as a set of independent linear lassiers for interations
between moleules and eah target protein, whih are trained without sharing any information
of known ligands between dierent targets. In other words, using Dira kernel for proteins
amounts to performing lassial learning independently for eah target, whih is our baseline
approah.
• The multitask kernel between two targets t, t′ is dened as:
Kmultitask(t, t
′) = 1 +KDirac(t, t
′) .
This kernel, originally proposed in the ontext of multitask learning Evgeniou et al. (2005),
removes the orthogonality of dierent proteins to allow sharing of information. As explained in
Evgeniou et al. (2005), plugging Kmultitask in (4) amounts to deomposing the linear funtion
used to predit interations as a sum of a linear funtion ommon to all GPCRs and of a linear
funtion spei to eah GPCR:
f(l, t) = w⊤Φ(l, t) = w⊤generalΦlig(l) + w
⊤
t Φlig(l) .
A onsequene is that only data related to the the target t are used to estimate the spei
vetor wt, while all data are used to estimate the ommon vetor wgeneral. In our framework
this lassier is therefore the ombination of a target-spei part aounting for target-spei
properties of the ligands and a global part aounting for general properties of the ligands
aross the targets. The latter term allows to share information during the learning proess,
while the former ensures that speiities of the ligands for eah target are not lost.
• The hierarhy kernel. Alternatively we ould propose a new kernel aimed at enoding the
similarity of proteins with respet to the ligands they bind. In the GLIDA database indeed,
GPCRs are grouped into 4 lasses based on sequene homology and funtional similarity: the
rhodopsin family (lass A), the seretin family (lass B), the metabotropi family (lass C) and
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some smaller lasses ontaining other GPCRs. The GLIDA database further subdivides eah
lass of targets by type of ligands, for example amine or peptide reeptors or more spei
families of ligands. This also denes a natural hierarhy that an be used to ompare GPCRs.
The hierarhy kernel between two GPCRs was therefore dened as the number of ommon
anestors in the orresponding hierarhy plus one, that is,
Khierarchy(t, t
′) = 〈Φh(t),Φh(t
′)〉,
where Φh(t) ontains as many features as there are nodes in the hierarhy, eah being set to 1
if the orresponding node is part of t's hierarhy and 0 otherwise, plus one feature onstantly
set to one that aounts for the "plus one" term of the kernel.
• The binding poket kernel. Beause the protein-ligand reognition proess ours in 3D
spae in a poket involving a limited number of residues, we tried to desribe the GPCR
spae using a representation of this poket. The diulty resides in the fat that although
the GPCR sequenes are known, the residues forming this poket and its preise geome-
try are a priori unknown. However, the two available X-Ray strutures, together with
mutagenesis data showed that the binding pokets are situated in a similar region for all
GPCRs (Kratohwil et al., 2005). In order to identify residues potentially involved in the
binding poket of GPCRs of unknown struture studied in this work, we proeeded in several
steps. (a) The two known strutures (PDB entries 1U19 and 2RH1) were superimposed using
the STAMP algorithm (Russell and Barton, 1992). In the superimposed strutures, the retinal
and 3-(isopropylamino)propan- 2-ol ligands are very lose, whih is in agreement with global
onservation of binding pokets, as shown on Figure 1. (b) The strutural alignment of bovine
rhodopsin and of human β2-adrenergi reeptor was used to generate a sequene alignment of
these two proteins. () For both strutures, in order to identify residues potentially involved in
stabilizing interations with the ligand (residues of the poket), we seleted residues that pre-
sented at least one atom situated at less than 6 from at least one atom of the ligand. Figure 2
shows that these two pokets learly overlap, as expeted. (d) Residues of the two pokets
(as dened in ()) were labeled in this strutural sequene alignment. These residues were
found to form small sequene lusters that were in orrespondene in this alignment. These
lusters were situated mainly in the apial region of transmembrane segments and inluded a
few extraellular residues. (e) All studied GPCR sequenes, inluding bovine rhodopsin and
of human β2-adrenergi reeptor were aligned using CLUSTALW (Chenna et al., 2003) with
Blosum matries (Heniko and Heniko, 1992). For eah protein, residues in orrespondene
with a residue of the binding poket (as dened above) of either bovine rhodopsin or human
β2-adrenergi reeptor were retained. This lead to a dierent number of residues per protein,
beause of sequene variability. For example, in extraellular regions, some residues from
bovine rhodopsin or human β2-adrenergi reeptor had a orresponding residue in some se-
quenes but not in others. In order to provide a homogeneous desription of all GPCRs, in the
list of residues initially retained for eah protein, only residues situated at positions onserved
in almost all GPCRs were kept. (f) Eah protein was then represented by a vetor whose
elements orresponded to a potential onserved poket. This desription, although appearing
as a linear vetor lled with amino aid residues, impliitly odes for a 3D information on the
reeptor poket, as illustrated on Figure 2. These vetors were then used to build a kernel
that allows omparison of binding pokets. The lassial way to represent motifs of onstant
length as xed length vetors is to enode the letter at eah position by a 20-dimensional
binary vetor indiating whih amino aid is present, resulting in a 180-dimensional vetor
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representations. In terms of kernel, the inner produt between two binding poket motifs in
this representation is simply the number of letters they have in ommon at the same positions:
Kpb(x, x
′) =
l∑
i=1
δ(x[i], x′[i]),
where l is the length of the binding poket motifs (31 in our ase), x[i] is the i-th residue in
x and δ(x[i], x′[i]) is 1 if x[i] = x′[i], 0 otherwise. This is the baseline poket binding kernel.
Alternatively, using a polynomial kernel of degree p over the baseline kernel is equivalent, in
terms of feature spae, to enoding p-order interations between amino aids at dierent posi-
tions. In order to assess the relevane of suh non-linear extensions we tested this polynomial
poket binding kernel,
Kppb(x, x
′) =
(
Kpb(x, x
′) + 1
)p
.
We only used a degree p = 2, although a more areful hoie of this parameter ould further
improve the performanes.
• The binding poket hierarhy kernel. Beause of the link between binding pokets and ligand
reognition, we also dened a new hierarhy based on the sequene alignment of the binding
poket amino aid vetors without gaps. To do this, we used a PAM matrix with high values
of gap insertion and extension to ompare eah ouple of GPCR vetors. The obtained sores
were used in UPGMA (Unweighted Pair Group Method with Arithmeti mean) to determine
a binding poket similarity based hierarhy. We obtained a tree omparable to phylogeneti
trees, and that happens to be share many substrutures with the GLIDA hierarhy.
Figure 1: Representation of the binding poket of β2-adrenergi reeptor (in red) and bovine
Rhodopsin (in blak) viewed from the extraellular surfae. On the enter of the poket, 3-
(isopropylamino)propan-2-ol and is-retinal have been represented to show the size and the position
of the poket around eah ligand. Figure drawn with VMD (Humphrey et al., 1996).
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Figure 2: 3-(isopropylamino)propan-2-ol and the protein environment of β2-adrenergi reep-
tor as viewed from the extraellular surfae. Amino aid side hains are represented for 6 of
the 31 residues (in yan, blue and red) of the binding poket motif. Transmembranes helix
and 3-(isopropylamino)propan-2-ol are olored in blak and red respetively. Figure drawn with
VMD (Humphrey et al., 1996).
3 Data
We used the GLIDA GPCR-ligand database (Okuno et al., 2006) whih inludes 22964 known lig-
ands for and 3738 GPCRs from human, rat and mouse. The ligand base ontains highly diverse
moleules, from ions and very small moleules up to peptides. In order to eliminate unwanted
moleules suh as inorgani ompounds and moleules with unsuitable moleular weights, we l-
tered the GLIDA ligand base using the lter program (OpenEye Sienti Software) with standard
parameters. The most important ltering feature here was to keep moleules of moleular weights
ranging from 150 Da to 450 Da. Overall, the GLIDA ligand base was ltered in order to retain
moleules that had the physio- hemial harateristis of drugs. This lter retained 2688 moleules.
Beause the GLIDA ligand base ontains a few dupliates, we eliminated these redundanies, whih
lead to 2446 dierent moleules, available under a 2D desription les and giving 4051 interations
with the human GPCRs. Elimination of dupliates present in the GLIDA base was important here
beause it ould have lead to overtting in the learning step. For eah positive interation given
by this restrited set, we generated a negative interation involving the same reeptor and one of
the ligands that was in the database and was not indiated as one of its ligands. This probably
generated some false negative points in our benhmark, and it would be interesting to use experi-
mentally tested negative interations. We loaded the sequenes of all GPCRs that are able to bind
any of these ligands, whih lead to 80 sequenes, all orresponding to human GPCRs. In the GLIDA
database, GPCRs are lassied in a hierarhy (as mentioned above) whih was also loaded for use
in the hierarhy kernel.
4 Results
We ran two dierent sets of experiments on this dataset in order to illustrate two important points.
In a rst set of experiments, for eah GPCR, we 5-folded the data available, i.e. the line of the
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Ktar\Klig 2D Tanimoto 3D pharmaophore
Dira 86.2 ± 1.9 84.4± 2.0
multitask 88.8 ± 1.9 85.0± 2.3
hierarhy 93.1 ± 1.3 88.5± 2.0
binding poket 90.3 ± 1.9 87.1± 2.3
poly binding poket 92.1 ± 1.5 87.4± 2.2
binding poket hierarhy 93.0 ± 1.4 90.0± 2.1
Table 1: Predition auray for the rst experiment with various ligand and target kernels.
interation matrix orresponding to this GPCR. The lassier was trained with four folds and the
whole data from the other GPCRs, i.e., all other lines of the interation matrix. The predition
auray for the GPCR under study was then tested on the remaining fold. The goal of these rst
experiments was to evaluate if using data from other GPCRs improved the predition auray for
a given GPCR. In a seond set of experiments, for eah GPCR we trained a lassier on the whole
data from the other GPCRs, and tested on the data of the onsidered GPCR. The goal was to
assess how eient our hemogenomis approah would be to predit the ligands of orphan GPCRs.
In both experiments, the C parameter of the SVM was seleted by internal ross validation on the
training set among 2i, i ∈ {−8,−7, . . . , 5, 6}.
For the rst experiment, sine learning an SVM with only one training point does not really
make sense and an lead to "anti-learning" less than 0.5 performanes, we set all results r involving
the Dira GPCR kernel on GPCRs with only 1 known ligand to max(r, 0.5). This is to avoid any
artefatual penalization of the Dira approah and make sure we measure the atual improvement
brought by sharing information aross GPCRs.
Figure 3: GPCR kernel Gram matries (Ktar) for the GLIDA GPCR data with multitask, hierarhy,
binding poket and binding poket hierarhy kernels.
Table 1 shows the results of the rst experiments with all the ligand and GPCR kernel ombi-
nations. For all the ligand kernels, one observes an improvement between the individual approah
(Dira GPCR kernel, 86.4%) and the baseline multitask approah (multitask GPCR kernel, 88.4%).
The latter kernel is merely modeling the fat that eah GPCR is uniformly similar to all other
GPCRs, and twie more similar to itself. It does not use any prior information on the GPCRs,
and yet, using it improves the global performane with respet to individual learning. Using more
informative GPCR kernels further improves, sometimes onsiderably, the predition auray. In
partiular, the hierarhy kernels add more than 4.5% of preision with respet to naive multitask
approah. All the other informative GPCR kernels also improve the performane. The polynomial
binding poket kernel and the poket binding hierarhy kernels are almost as eient as the hierar-
hy kernel, whih is an interesting result. Indeed, one ould fear that using the hierarhy kernel, for
the onstrution of whih some knowledge of the ligands may have been used, ould have introdued
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bias in the results. Suh bias is ertainly absent in the binding poket kernel. The fat that the
same performane an be reahed with kernels based on the mere sequene of GPCRs' pokets is
therefore an important result. Figure 3 shows four of the GPCR kernels. The baseline multitask is
shown as a omparison. Interestingly, many of the subgroups dened in the hierarhy an be found
in the binding poket kernel, that is, they are retrieved from the simple information of the binding
poket sequene. This phenomenon is even more visible for the binding poket hierarhy kernel that
is based on the hierarhy built from the binding poket alignment sores.
Figure 4: Improvement (as a performane ratio) of the hierarhy GPCR kernel against the Dira
GPCR kernel as a funtion of the number of training samples available. Restrited to [2 − 200]
samples for the sake of readability.
The 3D kernel for the ligands, on the other hand, did not perform as well as the 2D kernel. This
an be either explained by the fat the the pharmaophore kernel is not suited to this problem, or
by the fat that hoosing the onformer of the ligand is not a trivial task. This point is disussed
below.
Figure 4 illustrates how the improvement brought by the hemogenomis approah varies with
the number of available training points. As one ould have expeted, the strongest improvement is
observed for the GPCRs with few (less than 20) training points (i.e., less than 10 known ligands sine
for eah known ligand an artiial non-ligand was generated). When more training points beome
available, the improvement is less important, and sharing the information aross the GPCRs an
even degrade the performanes. This is an important point, rst beause, as showed on Figure 5,
many GPCRs have few known ligands (in partiular, 11 of them have only two training points),
and seond beause it shows that when enough training points are available, individual learning will
probably perform as well as or better than our hemogenomis approah.
Our seond experiment intends to assess how our hemogenomis approah an perform when
prediting ligands for orphan GPCRs, i.e., with no training data available for the GPCR of interest.
Table 2 shows that in this setting, individual learning performs random predition. Naive multitask
approah does not improve muh the performane, but informative kernels suh as hierarhial and
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Figure 5: Distribution of the number of training points for a GPCR. Restrited to [2−200] samples
for the sake of readability.
Ktar\Klig 2D Tanimoto 3D pharmaophore
Dira 50.0 ± 0.0 50.0± 0.0
multitask 56.8 ± 2.5 58.2± 2.2
hierarhy 77.4 ± 2.4 76.2± 2.2
binding poket 78.1 ± 2.3 76.6± 2.2
poly binding poket 76.4 ± 2.4 74.9± 2.3
binding poket hierarhy 75.5 ± 2.4 76.5± 2.2
Table 2: Predition auray for the seond experiment with various ligand and target kernels.
binding poket kernels ahieve 77.4% and 78.1% of preision respetively, that is, almost 30% better
than the random approah one would get when no data is available. Here again, the fat that the
binding poket kernel that only uses the sequene of the reeptor poket performs as well as the
hierarhy-based kernel is enouraging. It suggests that given a reeptor for whih nothing is known
exept its sequene, it is possible to make reasonable ligand preditions.
5 Disussion
We showed how sharing information aross the GPCRs by onsidering a hemogenomis spae of the
GPCR-ligand interation pairs ould improve the predition performanes. In addition, we showed
that using suh a representation, it was possible to make reasonable preditions even when no ligand
was known for a given GPCR, that is, to predit ligands for orphan GPCRs. Our approah is simply
to apply well known mahine learning methods in the onstruted hemogenomis spae. We used a
systemati way to build suh a spae by ombining a given representation of the ligands with a given
representation of the GPCRs into a binding-predition-oriented GPCR-ligand ouple representation.
This allows to use any ligand or GPCR desriptor or kernel existing in the hemoinformatis or
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bioinformatis literature, or new ones ontaining other prior information as we tried to propose in
this paper. Our experiments showed that the hoie of the desriptors was ruial for the predition,
and more sophistiated features for either the ligands or the GPCRs ould probably further improve
the performanes.
In all experiments, 3D pharmaophore kernels did not reah the performane of 2D kernels for
the ligands. This is apparently in ontradition we the idea that protein-ligand interation is a
proess ourring in the 3D spae, and that introdution of 3D information should inrease the
performane. Dierent explanations an be proposed. The hoie of the low energy onformer
was guided by the following idea. Beause only two ligand onformations bound to GPCR re-
eptors are available, it was not possible to derive any general information that ould be used to
hoose a potential bioative 3D onformer for eah moleule of the ligand base. In this ontext,
the only possible reasonable assumption was that, while interation with the reeptor will ertainly
perturb the onformational energy surfae of a exible ligand, high anity would be observed for
ligands that bind in a onformation that is not exeptionally dierent from a loal free state en-
ergy minimum (Boström, 2001). Although there exists a large number of methods for exploring
the onformation spae of a moleule, we used the Omega program that performs rapid systemati
onformer searh, beause it has been showed to present good performanes for retrieving bioa-
tive onformations (Boström et al., 2003). However, the set of parameters used to run Omega in
this study (beause of alulation time limitations) may not have allowed to reah a loal energy
minimum: generating a larger number of onformers, with a smaller RMSD lustering value may
have helped to nd better energy minima, and this ould be further evaluated. Moreover, some
studies report that the bioative onformation of a moleule an dier from the minimum energy
onformation, and that signiant strain energies an indeed be found for moleules in omplex
with proteins (Perola and Charifson, 2004). We annot rule out the possibility that this is the ase
for GPCR ligands. In the future, resolution of additional 3D strutures in this family will help
to larify this point. One possible improvement of the method ould be to use homology models
for the GPCRs, dok the ligand base in the modeled binding pokets, and build a 3D ligand base
using, for eah moleule, the onformer assoiated to the best doking solution. In other families
of proteins, enzymes for example, where many strutures are available and an be used to dene
bioative onformers, the 3D pharmaophore kernel is expeted to improve performane, as observed
in a previous pure ligand-based study involving ligands in a given series, for whih the bioative
onformation an be inferred from a known 3D struture (Mahé et al., 2006).
Various evidene suggest that, within a ommon global arhiteture, a generi binding poket
mainly involving transmembrane regions hosts agonists, antagonists and allosteri modulators. In
order to identify this poket automatially, other studies report the use of sequene alignment and
the predition of transmembrane helies. Kratohwil et al. (2005) deteted hypervariable positions
in transmembrane helies for identiation of residues forming the binding poket. The under-
lying idea was that onserved residues were probably important for struture stabilization, while
variable positions were involved in ligand binding, in order to aommodate the wide spetrum of
moleules that are GPCR substrates. Using this method, they proposed potential binding pok-
ets for GPCRs, and found that the orresponding residues were frequently in the GRAP mutant
database for GPCRs (Kristiansen et al., 1996). Interestingly, these authors pointed that residues
orresponding to these hypervariable positions were found within a distane of 6 from retinal in
the rhodopsin X-Ray struture. Therefore, although we used a dierent method to automatially
extrat binding poket residues in the GPCR families, our results are in good agreement with this
study.
Interesting developments of this method ould inlude appliation to quantitative predition
of the binding anities, that would be straightforward using regression algorithms in the same
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hemogenomis spae. Another possibility is appliation to other important drug target families,
like enzymes or ion hannels (Hopkins and Groom, 2002), for whih most of the desriptors used for
the GPCRs in this paper ould diretly be used, and other, more spei ones ould be designed.
From a methodologial point of view, many reent developments in multitask learning (Vert et al.,
2006; Argyriou et al., 2007; Bonilla et al., 2008) ould be applied to generalize this hemogenomis
approah using, for example, other regularization methods.
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positions on β2-adrenergi reeptor 82 109 110 113 114 115 116 117 118 121 175 183 195 199 200
β2-adrenergi reeptor M W T D V L C V T I R N T Y A
5-hydroxytryptamine 5A reeptor V W I D V L C C T I I E S Y A
Adenosine A2b reeptor V L A V L V L T Q I I K K M V
Gamma-aminobutyri aid type B reeptor E D E E A V E G H T L G S F D
Relaxin 3 reeptor 2 L V L T V L N V Y I V G L Y Q
positions on β2-adrenergi reeptor 203 204 207 208 212 282 286 289 290 293 308 311 312 313 315 316
β2-adrenergi reeptor S S S F L F W F F N Y L N W G Y
5-hydroxytryptamine 5A reeptor S T A F L F W F F E K F L W G Y
Adenosine A2b reeptor N F C V L F W V H N M A I L S H
Gamma-aminobutyri aid type B reeptor G S A W E F L Y H R L T V G L V
Relaxin 3 reeptor 2 R V A F L F W N H T F T T C A H
Table 3: Residues of 5-hydroxytryptamine 5A reeptor, Adenosine A2b reeptor, Gamma-aminobutyri aid type B reeptor and Relaxin
3 reeptor 2 (shown as examples) aligned with β2-adrenergi reeptor binding site amino aids. the binding poket motif of β2-adrenergi
reeptor has been used as referene to determine residues involved in the formation of the binding site of the 79 other GPCRs. Bold
olumns orrespond to the residues shown on Figure 2.
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